Evidence map›Paper›PMID 41648740›Full record

ArticleESMO gastrointestinal oncology2024

Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study.

G Mazzoli, F Nichetti, K Shitara, R Cohen, S Lonardi, C Cremolini, M E Elez, J Chao, M Fakih, S J Klempner and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

G MazzoliMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
F NichettiMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
K ShitaraNational Cancer Center Hospital East, Kashiwa, Japan.
R CohenSorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP and INSERM, Unité Mixte de Recherche Scientifique 938, SIRIC CURAMUS, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France.
S LonardiMedical Oncology 3 and Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua.
C CremoliniUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
M E ElezDepartment of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain.
J ChaoDepartment of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte.
M FakihDepartment of Medical Oncology and Therapeutic Research, City of Hope Comprehensive Cancer Center, Duarte.
S J KlempnerMass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston.
P JayachandranDivision of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles.
S MaronMemorial Sloan Kettering Cancer Center, New York, USA.
D CowzerMemorial Sloan Kettering Cancer Center, New York, USA.
L FornaroUnit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
L SalvatoreOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome.
V ZhuMass General Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston.
Y AokiNational Cancer Center Hospital East, Kashiwa, Japan.
R CerantolaMedical Oncology 3 and Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua.
F BergamoMedical Oncology 3 and Medical Oncology 1, Istituto Oncologico Veneto IOV-IRCSS, Padua.
M SalatiDivision of Oncology, Department of Oncology and Hematology, University Hospital of Modena, PhD Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena.
M AmbrosiniMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
G SabellaFirst Pathology Unit, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy.
G RandonMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
M J OvermanDepartment of Gastrointestinal Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
T AndréSorbonne Université, Department of Medical Oncology, Hôpital Saint-Antoine, AP-HP and INSERM, Unité Mixte de Recherche Scientifique 938, SIRIC CURAMUS, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France.
F PietrantonioMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Programmed cell death protein 1 (PD-1) blockade improved the survival of patients with mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) tumors, leading to tumor-agnostic approval of pembrolizumab in this population. Whether anti-programmed death (ligand)-1 [PD-(L)1] agents may achieve similar efficacy in dMMR/MSI-H metastatic gastric cancer (mGC) compared to metastatic colorectal cancer (mCRC) is unclear. Materials and methods: We conducted a multicenter cohort study to collect data on patients with dMMR/MSI-H mGC or mCRC treated with anti-PD-(L)1 monotherapy globally at 17 tertiary cancer centers. Clinical features were balanced according to tumor type through the inverse probability of treatment weighting (IPTW) method. The primary endpoint was overall survival (OS), as evaluated from the first anti-PD-(L)1 administration. Results: The cohort included 398 mCRC and 121 mGC patients, with a median follow-up of 34.6 and 25.1 months, respectively. The two populations differed for several baseline clinical features: patients with mCRC had younger age (60 versus 68 years, Conclusions: Despite patients with dMMR/MSI-H mGC being enriched with poor prognostic factors as compared to the mCRC counterpart, anti-PD-(L)1 monotherapy's efficacy appears similar in the two tumor types.

Indexed as

colorectal cancergastric cancerimmunotherapyinverse probability of treatment weightingmicrosatellite instabilitymismatch repair

Identifiers

PMID41648740
PMCPMC12836713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.